Increasing prevalence of cardiovascular disorders and growing global geriatric population is expected to serve as a high impact rendering driver for the heart blocks treatment market over the forecast period. Furthermore, minimally invasive cardiovascular treatment and the evolution of pacemakers coupled with changing lifestyles, genetic disorders, and developing healthcare infrastructure are expected to boost the market growth. Minimally invasive cardiovascular surgeries are now preferred over open surgeries, owing to the advantages associated with it such as the lower risk of bleeding and infection, shorter duration of stay at hospital, shorter recovery duration, and minimal surgical scarring. Heart blocks treatment market is segmented on the basis of type, treatment, and end-use. On the basis of type, the market is classified into, first-degree heart block, second-degree heart block, and third-degree heart block.
As of 2013, first-degree heart block held the largest market share. Key factors attributing to its large share includes a rising prevalence of first-degree heart block due to improper lifestyle and lack of physical activity. Transcutaneous pacing (TCP), pacemaker, medication, and follow-up electrophysiology study are amongst treatment options included in the scope of the study. Pacemakers held the majority of the market share in 2013. Key factors attributing to the higher uses of pacemakers include its small size and non-reactive metallic encasing, easy to implant, automatic resynchronization of the heart, and enhances electric signal across the heart. Pacemakers are implanted just below the collar bone to be in proximity to the arterial chambers. These pacemakers help in improving the patient’s life quality, lower risk of heart-related problems, and death due to sudden cardiac events.
Geographically, the heart blocks treatment market is studied with respect to North America, Europe, Asia Pacific, and RoW. North America emerged as the most lucrative regional market owing to the presence of strong R&D, availability of advanced technology, favorable reimbursement policies, and increased patient awareness. Asia Pacific is expected to grow at a lucrative CAGR over the forecast period owing to economic development in countries such as India and China coupled with increasing healthcare expenditure, growing patient awareness pertaining to the heart-related disorders. Key players operating in heart blocks treatment include Boston Scientific Corporation, Medtronic Inc., BIOTRONIK SE & Co. KG., Sorin Group, and St. Jude Medical, Inc.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.